Aytu BioScience Inc (AYTU)
NASDAQ:AYTU
Want to see AYTU full AI Analyst Report?
Earnings Data
Report Date
Sep 29, 2026TBA (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
-0.28Last Year’s EPS
-2.93Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presents a mixed but constructive picture: EXXUA's initial commercial launch shows strong early traction with accelerating prescription and shipment trends, encouraging payer coverage and attractive unit economics, and the RxConnect program appears to be reducing access friction. Offsetting this are significant year-over-year declines in legacy revenue, a quarter with a net loss and negative adjusted EBITDA, an inventory write-down, and near-term gross-to-net and cash-use volatility while the launch investment continues. Given the early-stage but tangible commercial progress balanced against meaningful near-term financial headwinds, the tone is cautiously optimistic but still transitional.Company Guidance
Strong Early EXXUA Launch Momentum
EXXUA generated $2.4M in net revenue in the quarter (first meaningful commercial quarter) with more than 1,300 prescriptions written in Q3 and continued growth into April (over 920 prescriptions). Prescriptions progressed monthly from ~200 (Jan) to ~400 (Feb) to >700 (Mar) and +26% month-over-month in April.
Rapid Unit Growth and Channel Activity
Gross unit sales in Q3 were 3,335 units (1,807 30-count units and 1,528 titration units). Since launch total gross unit sales were 3,881 units (≈1,991 30-count; 1,890 titration). April shipments exceeded 1,300 units, a 51% sequential increase versus March.
Early Prescriber Adoption
More than 450 unique prescribers wrote EXXUA in the quarter, representing ~10–13% of the initial ~3,500–4,000 target prescriber universe. Prescriptions have been written in 41–42 states, including areas without a physical sales presence.
Encouraging Refill and Titration Signals
Early refill activity and high utilization of titration packs indicate tolerability and continuation: notable conversion from titration to 30-day supplies with refill activity beginning to appear despite a very small early patient base.
RxConnect and Payer Dynamics Performing Well
RxConnect is supporting access with a no-cost 14-day titration pack and guaranteed month 1–2 coverage for commercially insured patients. Within the RxConnect network, management reports approval rates over ~70% on prior authorizations and improving coverage across commercial, Medicaid and Medicare channels.
Attractive Unit Economics
Management expects EXXUA unit economics to be favorable: roughly 31% cost of goods sold and ~69% gross contribution margin before fixed costs; product includes a 28% royalty and a true-up on COGS, supporting attractive long-term margins (mid- to high-60% gross margins expected over time).
Balance Sheet Improvement from Warrant Amendment
Warrant amendments reduced derivative warrant liabilities and increased stockholders' equity by $26.4M at quarter end. Stockholders' equity rose to $35.1M on March 31, 2026, improving the balance-sheet presentation and reducing future noncash earnings volatility tied to warrant accounting.
AYTU Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AYTU Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $2.25 | $2.27 | +0.89% |
Feb 03, 2026 | $2.62 | $2.35 | -10.31% |
Nov 13, 2025 | $2.06 | $2.09 | +1.46% |
Sep 23, 2025 | $2.51 | $2.06 | -17.93% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Aytu BioScience Inc (AYTU) report earnings?
Aytu BioScience Inc (AYTU) is schdueled to report earning on Sep 29, 2026, TBA (Confirmed).
What is Aytu BioScience Inc (AYTU) earnings time?
Aytu BioScience Inc (AYTU) earnings time is at Sep 29, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AYTU EPS forecast?
AYTU EPS forecast for the fiscal quarter 2026 (Q4) is -0.28.